Shots:

• Health Canada has approved Hulio- a biosimilar referencing AbbVie’s Humira (adalimumab)- which is now available in Canada. It is licensed from Fujifilm Kyowa Kirin and approved for all adalimumab indications
• The approval was based on an analytical- pre/ clinical program. Fujifilm Kyowa Kirin conducted a P-III ARABESC study that demonstrated no differences in terms of safety- efficacy- and immunogenicity compared to its reference product in patients with RA
• Fujifilm Kyowa Kirin and Viatris aims to expand patient access to more affordable biosimilar medicines across the globe- including in Canada

 ­ Ref: Newswire Canada | Image: Vaitris